Market Movers: Perrigo Company (PRGO) Gains 4.31% to Close at $36.77 May 13

Equities Staff  |

Today, Perrigo Company plc (NYSE:PRGO) was up $1.52 to close Friday at $36.77.

The company started at $35.50 and shares fluctuated between $37.19 and $35.13 with 3,124,516 shares trading hands.

Perrigo Company is averaging 1,595,075 shares traded over the last 30 days. They have shed 8.70% YTD.

Perrigo Company expects its next earnings on 2022-08-10.

For technical charts, analysis, and more on Perrigo Company visit the company profile.

About Perrigo Company plc

Perrigo Company plc is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer 'own brand' labels. Additionally, Perrigo is a Top 5 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries. The Company also commercializes and manufactures generic prescription products in the U.S.

To get more information on Perrigo Company plc and to follow the company's latest updates, you can visit the company's profile page here: Perrigo Company plc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I
Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users
Squarespace Beats Revenue Estimates With Record Q1
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million
How To Trade in a Bearish Market
AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement



Market Movers

Sponsored Financial Content